Insulin-, glucagon-, and somatostatin-containing cells, identified by immunofluorescent staining, were quantitated morphometrically in sections of pancreas obtained from diabetic and nondiabetic humans and rats. Both the volume density and number of somatostatin-and glucagon-containing cells were The other diabetic pancreas was obtained from a 31-yearold white female with a 29-year history of juvenile-type diabetes who died of renal insufficiency. Grossly, the pancreas was indurated and microscopic examination revealed acute pancreatitis. Islets were sparse and small, consisting largely of A-cells. No B-cells were noted.
gon-containing cells were significantly increased in the islets of juvenile-type human diabetics and of streptozotocin diabetic rats.
Somatostatin, or a somatostatin-like immunoreactive material, has recently been identified in pancreatic islets (1) (2) (3) (4) and localized to the D-cells (5) (6) (7) (8) . Previous reports of increased numbers of D-cells (or Al-cells) in the islets of diabetic humans (9) , rats (10) or guinea-pigs (11) , together with demonstrations of somatostatin's potent inhibitory action upon insulin and glucagon release (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) , prompted this morphometric comparison of somatostatin-, insulin-, and glucagoncontaining cells in the pancreases of diabetic and nondiabetic humans and rats by means of immunofluorescent staining techniques §.
MATERIALS AND METHODS
Light Microscopy Methods. Pieces of tissue were fixed in Bouin's solution, dehydrated in alcohol, and embedded in paraffin. Sections of 5 ,um thickness were stained with aldehyde fuchsin (23) , phosphotungstic acid-hematoxylin (24) Control experiments were performed using the specific antiserum absorbed with the corresponding antigen, 200,g of cyclic somatostatin (a gift of Drs. J. Rivier and R. Guillemin), 50 jig of glucagon, or 2 units of insulin per ml of undiluted antiserum. After removal of the paraffin, sections were rehydrated and incubated for 2 hr with anti-somatostatin, anti-insulin, or anti-glucagon serum. After rinsing in phosphate-buffered saline, the sections were incubated with the fluorescein-labeled antibody for 1 In the islets of the four normal humans (Fig. la) (Fig. id) , which consisted largely of glucagon-immunofluorescent cells (Fig. le) ; somatostatin-immunofluorescent cells were also abundant (Fig. if) . Morphometric analyses revealed both cell types to be significantly increased above the control values (Table 1) . Studies in normal and streptozotocin-diabetic rats In 60 islets examined in the pancreases of four nondiabetic rats, morphometric analyses (Table 2 ) of the three types of immunofluorescent cells (Fig. 2a-c) were rather similar to the findings in the four nondiabetic humans. In the four diabetic rats (Fig. 2d-f) insulin-immunofluorescent cells were sharply reduced both in volume density and percent of total immunofluorescent cells per islet, whereas glucagon-immunofluorescent and somatostatin-immunofluorescent cells were significantly increased (Table 2) .
Calculations for entire pancreases revealed a reduction in total islet volume in the diabetic pancreases to approximately half the control values ( Table 3) . The volume and number of insulin-immunofluorescent cells per diabetic pancreas were reduced significantly below the control values. The total volume and number of glucagon-immunofluorescent cells per pancreas did not differ significantly from normal, whereas the total volume of somatostatin-immunofluorescent cells per pancreas was 2.5 times normal and the total number was almost twice normal (Table 3) .
DISCUSSION
Current knowledge of the pathology of islets of Langerhans in human diabetes is based entirely on routine autopsy material with use of conventional staining methods (27, 28) . The present studies of portions of two relatively fresh human diabetic pancreases by immunofluorescent techniques revealed a total absence of insulin-immunofluorescent cells and an abundance of glucagon-immunofluorescent and somatostatin-immunofluorescent cells in the 60 randomly chosen islets examined when compared to islets of nondiabetic subjects. However, in view of the sparsity of islets in most of the sections of the two diabetic pancreases studied, an absolute increase in the total pancreatic population of the latter cell types seems unlikely. The results in rats with insulin-independent streptozotocin diabetes of long duration were similar to the humans at the "within-islet" level. A highly significant decrease in the number and volume of insulin-immunofluorescent cells per pancreas and an increase in the total number and volume of somatostatin-immunofluorescent cells per pancreas were observed in the diabetic rats. But the number and volume of glucagon-immunofluorescent cells per pancreas did not dif- Table 1 . Insulin-, glucagon-, and somatostatinimmunofluorescent cells in the islets of chronic juveniletype diabetic subjects, and of nondiabetic subjects We interpret these findings as evidence of D-cell hypertrophy and hyperplasia in diabetes, the physiologic and pathophysiologic significance of which remains to be determined. A change in the numbers and/or volume of cells (15, 19) , raises the possibility of a compensatory D-cell response, perhaps to the excessive glucagon secretion of diabetes (22, 29 (30) .
